论文部分内容阅读
目的观察恩度联合顺铂胸腔内灌注治疗晚期非小细胞肺癌合并恶性胸腔积液的疗效和毒副反应。方法 42例晚期非小细胞肺癌合并胸腔积液患者分成顺铂组(对照组)和恩度联合顺铂组,每组21例,分别注入顺铂及顺铂、恩度联用,每周1次,连用3周后评价疗效及生活质量。结果顺铂、恩度联用组治疗胸水有效率及生活质量改善率比顺铂单用组有明显提高(P<0.05)。结论恩度联合顺铂治疗晚期非小细胞肺癌合并恶性胸腔积液疗效显著,不良反应小,值得临床推广应用。
Objective To observe the curative effect and toxicity of entecavir combined with cisplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion. Methods Forty-two patients with advanced non-small cell lung cancer and pleural effusion were divided into cisplatin group (control group) and Endostar combined cisplatin group (21 cases in each group), with cisplatin and cisplatin respectively. Times, once every 3 weeks to evaluate the efficacy and quality of life. Results The improvement rate of pleural effusion and quality of life in Cisplatin and Ende combined therapy group were significantly higher than those in cisplatin alone group (P <0.05). Conclusions Endood combined with cisplatin in the treatment of advanced non-small cell lung cancer with malignant pleural effusion has a significant effect and little adverse reaction, which is worthy of clinical application.